Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04367090
Recruitment Status : Active, not recruiting
First Posted : April 29, 2020
Last Update Posted : April 27, 2022
Sponsor:
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Brief Summary:

The primary objective of the study is to study the pharmacokinetics of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.

The secondary objective of the study is to evaluate the safety and efficacy (ORR) of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.


Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: Docetaxel, trastuzumab Drug: Pyrotinib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Single-arm and Multi-center Pharmacokinetic Study of Pyrotinib and Docetaxel Plus Trastuzumab in Patients With HER2 Positive Recurrent or Metastasis Breast Cancer.
Actual Study Start Date : July 7, 2020
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : December 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Pyrotinib and docetaxel plus trastuzumab Drug: Docetaxel, trastuzumab
Docetaxel and trastuzumab once per cycle

Drug: Pyrotinib
Pyrotinib 400/320 mg orally daily




Primary Outcome Measures :
  1. Pharmacokinetic parameter: Cmax of pyrotinib and docetaxel [ Time Frame: Approximately 2 months ]
    Peak Plasma Concentration (Cmax) of pyrotinib

  2. Pharmacokinetic parameter: AUC of pyrotinib and docetaxel [ Time Frame: Approximately 2 months ]
    Area under the plasma concentration versus time curve (AUC) of pyrotinib and docetaxel


Secondary Outcome Measures :
  1. ORR [ Time Frame: Approximately 17 months ]
    Objective Response Rate

  2. AEs+SAEs [ Time Frame: Approximately 17 months ]
    Adverse Events and Serious Adverse Events

  3. λz [ Time Frame: Approximately 6 months ]
  4. The incidence of≥3 grade diarrhea with different treatment [ Time Frame: Approximately 17 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. HER2 positive recurrent or metastasis breast cancer.
  2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  3. Adequate organ function.
  4. Signed, written inform consent obtained prior to any study procedure.

Exclusion Criteria:

  1. Patients received more than 1 line of chemotherapy or immunotherapy in the phase of recurrence / metastasis.
  2. History of HER tyrosine kinase inhibitors or monoclonal antibody for breast cancer in any treatment setting,except trastuzumab ,or Pertuzumab used in the neo-adjuvant or adjuvant setting.
  3. Assessed by the investigator to be unable receive systemic chemotherapy.
  4. History of other malignancy within the last 5 years,except for carcinoma in situ of cervix,basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent.
  5. Pregnant or lactating women,or for women of childbearing potential unwilling to use a highly-effective contraception during of the study treatment and for at least 7 months after the last dose of study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04367090


Locations
Layout table for location information
China, Guangdong
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China, 510000
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Layout table for additonal information
Responsible Party: Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier: NCT04367090    
Other Study ID Numbers: BLTN-Ig
First Posted: April 29, 2020    Key Record Dates
Last Update Posted: April 27, 2022
Last Verified: December 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Docetaxel
Trastuzumab
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological